Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.73 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699319 | 0.87 | SCN9A (0.66) | SCN9AMCHR1METTP53 | |
| SCHEMBL16699624 | 0.84 | SCN9A (1.00) | SCN9AMCHR1TP53HRH1CYP2D6 | |
| SCHEMBL16699095 | 0.83 | SCN9A (0.73) | SCN9AMCHR1METTP53HRH1 | |
| SCHEMBL16699091 | 0.83 | SCN9A (0.73) | SCN9AMCHR1METTP53HRH1 | |
| SCHEMBL16698841 | 0.82 | SCN9A (1.00) | SCN9AMCHR1METMAPT | |
| SCHEMBL16699310 | 0.82 | SCN9A (0.76) | SCN9AMCHR1METHRH1 | |
| SCHEMBL16699577 | 0.81 | SCN9A (1.00) | SCN9AMCHR1TP53HRH1CYP2D6 | |
| SCHEMBL16699557 | 0.76 | SCN9A (1.00) | SCN9AMCHR1METTP53HRH1 | |
| SCHEMBL16699555 | 0.76 | SCN9A (1.00) | SCN9AMCHR1METTP53HRH1 | |
| SCHEMBL16707109 | 0.75 | SCN9A (0.68) | SCN9AMCHR1METTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | claimed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | claimed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | SCN9A 120/4885MCHR1 1621/4885MET 4186/4885 |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | SCN9A 120/4885MCHR1 1621/4885MET 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.